Trump Administration Pursues Deals Across 30 Industries Ahead of Midterms

The Trump administration is actively pursuing deals across up to 30 critical industries, including pharmaceuticals, semiconductors, AI, and energy, aiming to strengthen U.S. manufacturing, reduce reliance on China, and secure supply chains ahead of the 2026 midterm elections. The administration is leveraging government power by offering tariff relief in exchange for concessions, revenue guarantees, or equity stakes in companies, targeting those deemed vital to national and economic security. Pharmaceutical companies like Eli Lilly, Pfizer, and AstraZeneca have received frequent White House engagement, with requests to increase production and consider U.S. headquarters relocations. These efforts are designed not only to stabilize key sectors and protect jobs but also to deliver visible political wins, with announcements planned to be made from the White House to maximize impact. While this aggressive dealmaking aims to boost investor confidence and demonstrate economic stewardship, analysts warn it could deepen government involvement in private markets and raise concerns about long-term competitiveness. The administration emphasizes this as a "whole-of-government approach" to safeguard the nation's economic security through fast-paced and strategic dealmaking.